Ascendis Pharma (ASND)
(Delayed Data from NSDQ)
$139.65 USD
-0.01 (-0.01%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $139.50 -0.15 (-0.11%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Ascendis Pharma A/S [ASND/]
Reports for Purchase
Showing records 121 - 140 ( 303 total )
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Skytrofa Sales In-Line with Survey Results, Launch Outlook;All Eyes on PTH
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Survey Highlights SKYTROFA''s Safety and Efficacy - Reveals Payer Headwinds
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Generating Value in 2022 with Key Catalysts in All Programs & SKYTROFA Launch
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Starting the New Year Off Right: TC-hGH Receives EU Approval for Pediatric GHD
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
R&D Day: Looking Ahead to More Pipeline Progress and Multiple Catalysts in ''22
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
84-Wk TC-PTH Data Set Stage for Q1:22 Ph3 Readout; TC-hGH Positive CHMP Opinion
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Q3: Ascending to Greater Heights with SKYTROFA Launch & Pipeline Progress
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Sky''s the Limit - SKYTROFA U.S. Launch Underway; PT to $191
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Normalized and Stabilized BMD Z-Scores Bolster TC-PTH''s Efficacy Profile
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L